FINWIRES · TerminalLIVE
FINWIRES

ASX:4DX

14 stories mentioning ASX:4DXUpdated 13d ago

Every FINWIRES story that references ASX:4DX, newest first.

Asia

ASX Biggest Losers

Here are the ASX-listed companies with the biggest losses on Friday.EQ Resources (ASX:EQR): -10%, AU$0.22Mesoblast (ASX:MSB): -10%, AU$2.50Orezone Gold (ASX:ORE): -8%, AU$2.07Ora Banda Mining (ASX:OBM): -8%, AU$0.99Regis Resources (ASX:RRL): -8%, AU$5.69Sunrise Energy Metals (ASX:SRL): -7%, AU$15.744DMedical (ASX:4DX): -7%, AU$3.49Weebit Nano (ASX:WBT): -7%, AU$6.04Elsight (ASX:ELS): -7%, AU$6.74Metals X (ASX:MLX): -7%, AU$1.35

ASX 200ASX:4DXASX:ELSASX:EQRASX:MLXASX:MSBASX:OBMASX:OREASX:RRLASX:SRLASX:WBT
Asia

Australian Shares Flat; 4DMedical's Imaging Technology Secures TGA Approval

Australian shares closed flat with a positive bias on Friday as investors reacted to a media report that OpenAI's initial public offering could be delayed.The S&P/ASX 200 Index was little changed to close at 8,764.20.Technology shares retreated after a sell-off in Apple shares after the technology giant disclosed price increases, as the prices of memory and storage chips rocketed, as well as a report that OpenAI is mulling a delay to its IPO until next ​year.Brent crude oil futures were trading around $73 per barrel. Meanwhile, gold steadied around $4,000 per ounce.On the domestic front, Westpac said there is around a one-in-four probability of an economic contraction in the June quarter in Australia, based on historical patterns and an estimated 10% chance of a negative quarter in the September quarter.The Westpac-Now indicator projected gross domestic product (GDP) growth of around 0.2% on a quarterly basis in the June quarter, with a range of 0.16% contraction to 0.4% growth.In company news, 4DMedical (ASX:4DX) secured Therapeutic Goods Administration (TGA) approval and inclusion on the Australian Register of Therapeutic Goods for its non-contrast ventilation-perfusion imaging software CT:VQ, enabling commercial use across Australia.HMC Capital (ASX:HMC) confirmed that all conditions precedent for its strategic partnership with KKR in the HMC Energy Platform have been satisfied, including approvals from the Australian Competition and Consumer Commission and the Foreign Investment Review Board, with completion expected around June 30.Lastly, BHP Group (ASX:BHP) appointed Edgar Basto as chief enterprise performance officer, effective Sept. 1. Basto is currently serving as the firm's chief operating officer.

ASX 200ASX:4DXASX:BHPASX:HMC
Asia

Update: 4DMedical's Imaging Technology Secures TGA Approval, Shares Fall 9%

(Update to add stock movement in the headline and the fifth paragraph)4DMedical (ASX:4DX) secured Therapeutic Goods Administration (TGA) approval and inclusion on the Australian Register of Therapeutic Goods for its non-contrast ventilation-perfusion imaging software CT:VQ, enabling commercial use across Australia, according to a Friday Australian bourse filing.The technology derives regional ventilation and perfusion information from standard non-contrast computed tomography (CT) scans without the need for injections, contrast agents, or nuclear medicine infrastructure, per the filing.The company said CT:VQ is well-positioned for scalable adoption across both urban and regional healthcare settings in Australia, where high CT scanner density could help improve access to functional lung imaging, the filing said.The company will now seek Medicare reimbursement through the Medical Services Advisory Committee, backed by clinical and health-economic evidence as well as real-world usage data, the filing added.Its shares fell 9% in recent trading on Friday.

ASX:4DX
Asia

4DMedical's Imaging Technology Secures TGA Approval

4DMedical (ASX:4DX) secured Therapeutic Goods Administration (TGA) approval and inclusion on the Australian Register of Therapeutic Goods for its non-contrast ventilation-perfusion imaging software CT:VQ, enabling commercial use across Australia, according to a Friday Australian bourse filing.The technology derives regional ventilation and perfusion information from standard non-contrast computed tomography (CT) scans without the need for injections, contrast agents, or nuclear medicine infrastructure, per the filing.The company said CT:VQ is well positioned for scalable adoption across both urban and regional healthcare settings in Australia, where high CT scanner density could help improve access to functional lung imaging, the filing said.The company will now seek Medicare reimbursement through the Medical Services Advisory Committee, backed by clinical and health-economic evidence as well as real-world usage data, the filing added.

ASX:4DX
Asia

4DMedical Says JPMorgan Chase Acquires 5.27% Stake

4DMedical (ASX:4DX) said JPMorgan Chase and its affiliates acquired voting power of 5.27% in the firm as of June 19, becoming a substantial holder, according to a Wednesday Australian bourse filing.JPMorgan Chase now holds 31.4 million ordinary shares of the firm.

ASX:4DX
Asia

4DMedical Launches CLEAR Clinical Program to Target $3 Billion Pulmonary Embolism Market

4DMedical (ASX:4DX) launched CLEAR, a clinical evidence program designed to accelerate entry of its CT:VQ imaging technology into the acute pulmonary embolism market, targeting a $3 billion obtainable market in the US, according to a Tuesday Australian bourse filing.The company said the core CLEAR study, which stands for Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism, is a multi-center, multinational, prospective, observational study putting CT:VQ head-to-head with computed tomography pulmonary angiography in patients with suspected pulmonary embolism, the filing added.4DMedical has entered into a clinical research agreement with Mass General Brigham-affiliated teaching hospitals as the lead site for CLEAR, it added.

ASX:4DX
Asia

4DMedical to Acquire Austrian Medical AI Company Contextflow in Cash, Stock Deal; Shares Up 6%

4DMedical (ASX:4DX) signed a binding agreement to acquire Austria-based contextflow, a medical technology company specializing in lung cancer screening and advanced artificial intelligence-driven thoracic imaging, in a deal that includes upfront cash payments of about AU$18.6 million, according to a Monday Australian bourse filing.The deal also includes 56,235 ordinary shares, plus an earn-out of up to 2.6 million zero-exercise-price options over two years subject to performance milestonesThe company said the acquisition establishes an immediate European commercial and clinical platform, with contextflow retaining about AU$30.8 million in accumulated tax losses.The acquisition introduces insurance reimbursement contracts in Germany and helps expand the company's CT:VQ product across the region, per the filing.4DMedical's shares jumped nearly 6% in recent Monday trade.

ASX:4DX
Asia

ASX Biggest Gainers

Here are the ASX-listed companies with the biggest gains on Friday.Electro Optic Systems (ASX:EOS): +15%, AU$11Elsight (ASX:ELS): +13%, AU$7.184DMedical (ASX:4DX): +12%, AU$3.74Judocapitol FP (ASX:JDO): +11%, AU$1.54Flight Centre Travel Group (ASX:FLT): +8%, AU$10.96West African Resources (ASX:WAF): +8%, AU$3.19Lindian Resources (ASX:LIN): +8%, AU$0.83Ora Banda Mining (ASX:OBM): +7%, AU$1.36Vulcan Energy Resources (ASX:VUL): +7%, AU$3.89Westgold Resources (ASX:WGX): +6%, AU$5.18

ASX 200ASX:4DXASX:ELSASX:EOSASX:FLTASX:JDOASX:LINASX:OBMASX:VULASX:WAFASX:WGX
Asia

4DMedical Enters Three-Year Commercial Deal With SimonMed Imaging; Shares Surge 11%

4DMedical (ASX:4DX) struck a three-year commercial deal with US medical imaging provider SimonMed Imaging covering the use of its advanced quantitative cardiopulmonary analysis technology, according to a Friday filing with the Australian bourse.SimonMed will deploy 4DMedical's CT:VQ and LDAf technology to support clinical decision making for pulmonary assessment at pricing that is based on 4DMedical's per-scan rates, per the filing."While the agreement is not immediately financially material, the deployment with SimonMed represents a clear commercial win for 4DMedical, and a material long-term opportunity," the company said.The deal with SimonMed, which operates more than 170 outpatient imaging centers in the US, represents CT:VQ's entry into the country's outpatient market.4DMedical shares surged 11% in recent Friday trade.

ASX:4DX
Asia

4DMedical Says Study Shows CT:VQ Imaging Product Lifts Lung Surgery Response Rate to 76%; Shares Up 3%

4DMedical (ASX:4DX) said a study evaluating its CT:VQ imaging product, published in the American Journal of Respiratory and Critical Care Medicine, shows that CT:VQ-guided patient selection would deliver a 76% response rate to lung volume reduction surgery (LVRS), compared with the current rate of 46%, according to a Tuesday Australian bourse filing.The company said CT:VQ derives functional ventilation and perfusion information from existing non-contrast CT scans, with improved pre-operative patient selection strengthening the economics of LVRS programs for hospitals by concentrating surgical resources on patients most likely to benefit.The company's shares were up 3% in recent Tuesday trade.

ASX:4DX
Asia

4DMedical's Year-to-Date Fiscal 2026 Operating Revenue Rises 12% Year on Year

4DMedical (ASX:4DX) said the operating revenue for year-to-date fiscal 2026 was AU$5 million, up 12% compared to the prior corresponding period, with gross margins exceeding 90%, according to a Thursday Australian bourse filing.It reported operating revenue of AU$4.5 million in the prior-year period, according to a separate filing.Receipts from customers in the fiscal third quarter ended March increased 18% year-over-year to AU$1.4 million, from AU$1.2 million.Underlying software-as-a-service revenue was up 24% year-over-year for the nine months to March, driven by increased penetration across business-to-business software-as-a-service sites and distributors.

ASX:4DX
Asia

4DMedical Says State Street Becomes Substantial Holder

4DMedical (ASX:4DX) said State Street and its subsidiaries have become a substantial holder in the company on April 24 with a stake of 5.01% or 29.6 million shares, according to a Tuesday Australian bourse filing.

ASX:4DX
Asia

4DMedical Secures One-Year Deal With GlaxoSmithKline

4DMedical (ASX:4DX) secured a one-year contract with GlaxoSmithKline, in collaboration with imaging data platform Flywheel Exchange, to provide its quantitative lung imaging analytics from May to support pulmonary drug development and clinical research, according to a Monday filing with the Australian bourse.Additionally, the company's CT:VQ imaging technology obtained UK Conformity Assessed certification, allowing for the commercial deployment across both public and private healthcare providers within the UK, the filing said.The company will also be included in the S&P/ASX 200 Index, effective before the open of trading on Monday, per the filing.4DMedical's shares rose around 1% in morning trade Monday.

ASX:4DX
Asia

ASX Biggest Losers

Here are the seven ASX-listed companies with the biggest losses on Friday.4D Medical (ASX:4DX): -5%, AU$6.08Evolution Mining (ASX:EVN): -4%, AU$13.30Whitehaven Coal (ASX:WHC): -3%, AU$8.13Alcoa (ASX:AAI): -3%, AU$96.50Westgold Resources (ASX:WGX): -3%, AU$6.25New Hope (ASX:NHC): -2%, AU$5.33Capricorn Metals (ASX:CMM): -2%, AU$11.53

ASX 200ASX:4DXASX:AAIASX:CMMASX:EVNASX:NHCASX:WGXASX:WHC

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:4DX in your portfolio
WheelAI
WheelAI
Analyze ASX:4DX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:4DX